Seroprevalence of hepatitis E virus in liver transplant patients in Turin, Italy.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Mar 2023
Historique:
pubmed: 24 7 2020
medline: 16 3 2023
entrez: 24 7 2020
Statut: ppublish

Résumé

Acute E hepatitis is usually a self-limited non-progressive disease; however, acute liver failure and death can occur in the presence of conditions such as pregnancy and chronic liver diseases. In immunocompromised individuals, such as transplant patients, acute hepatitis E virus (HEV) infection may evolve to chronic hepatitis with rapid progression to liver decompensation. At our center, serology for HEV is not routinely performed in transplant patients and serological status is investigated only based on clinical judgement. In this study, seroprevalence of HEV was evaluated in 217 patients (120 liver transplant recipients and 97 individuals diagnosed with acute or chronic hepatitis). Molecular evaluation of HEV-RNA was also performed. Thirteen patients (6%) showed positivity for HEV-IgG; in particular, 10/120 (8.3%), with concomitant presence of IgM and IgG in six and 3/97 (3.1%). None of the plasma samples tested by HEV-RNA was positive. As the detectable RNA window is narrow and an undetectable HEV-RNA result does not exclude recent infection and the transplant context per se represents a risk factor for chronic infection in patients infected with HEV, a routine diagnostic workflow including HEV should be taken into consideration, increasing awareness and knowledge of the basic and clinical aspects of the disease.

Sections du résumé

BACKGROUND BACKGROUND
Acute E hepatitis is usually a self-limited non-progressive disease; however, acute liver failure and death can occur in the presence of conditions such as pregnancy and chronic liver diseases. In immunocompromised individuals, such as transplant patients, acute hepatitis E virus (HEV) infection may evolve to chronic hepatitis with rapid progression to liver decompensation. At our center, serology for HEV is not routinely performed in transplant patients and serological status is investigated only based on clinical judgement.
METHODS METHODS
In this study, seroprevalence of HEV was evaluated in 217 patients (120 liver transplant recipients and 97 individuals diagnosed with acute or chronic hepatitis). Molecular evaluation of HEV-RNA was also performed.
RESULTS RESULTS
Thirteen patients (6%) showed positivity for HEV-IgG; in particular, 10/120 (8.3%), with concomitant presence of IgM and IgG in six and 3/97 (3.1%). None of the plasma samples tested by HEV-RNA was positive.
CONCLUSIONS CONCLUSIONS
As the detectable RNA window is narrow and an undetectable HEV-RNA result does not exclude recent infection and the transplant context per se represents a risk factor for chronic infection in patients infected with HEV, a routine diagnostic workflow including HEV should be taken into consideration, increasing awareness and knowledge of the basic and clinical aspects of the disease.

Identifiants

pubmed: 32700882
pii: S0031-0808.20.03877-X
doi: 10.23736/S0031-0808.20.03877-X
doi:

Substances chimiques

RNA, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-22

Auteurs

Elisa Zanotto (E)

Unit of Microbiology and Virology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Massimo Rittà (M)

Unit of Microbiology and Virology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Fabrizia Pittaluga (F)

Unit of Microbiology and Virology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Silvia Martini (S)

Unit of Gastrohepatology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Marco Ciotti (M)

Department of Clinical Microbiology and Virology, Tor Vergata University, Rome, Italy.

Rossana Cavallo (R)

Unit of Microbiology and Virology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Cristina Costa (C)

Unit of Microbiology and Virology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy - ezanotto@cittadellasalute.to.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH